logoThe People's Perspective on Medicine

Show 994: Learn How One Doctor Is Reversing Alzheimer’s (Archive)

An iterative, multifactorial, personalized approach to optimizing risk factors is critical to reversing Alzheimer's disease successfully.
Show 994: Learn How One Doctor Is Reversing Alzheimer’s (Arc...
Alzheimer’s disease research
Current time

Learn How One Doctor Is Reversing Alzheimer’s (Archive)

0% played0% buffered
Duration

Alzheimer’s disease is a prospect as frightening to many of us as cancer, and the treatment options are not promising. Most of the costly medications used in treating this type of dementia do little more than delay its progression by a few weeks or months. The idea that anything might be done to turn back the ravages of this memory robber has seemed an impossible dream.

Optimizing Multiple Factors for Cognitive Recovery:

Now, however, research shows that a novel, multi-faceted approach may be able to reverse cognitive decline. Nine of the first ten patients on this comprehensive, personalized therapeutic program have shown improvement. Not only have the markers of inflammation underlying Alzheimer’s disease become less severe, but they also have had lasting improvement in measures of memory and ability to function and reason. What are the elements and lessons of this therapeutic system?

This radio program first aired on May 30, 2015. We are offering it for re-broadcast on March 5, 2016. You will not want to miss it. Let friends and family know that this could be a game changer for people concerned about cognitive function.

Find a radio station near you or stream the audio live from a station that airs the show. Here is a link to all our participating stations. And if you live in an area where no public radio stations carry The People’s Pharmacy, please ask the program director to consider carrying the show. It is currently free to all public radio broadcasters.

This Week’s Guest:

Dale Bredesen, MD, is the Augustus Rose Professor of Neurology and Director of the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA. He is also Director of Neurodegenerative Disease Research at the David Geffen School of Medicine at UCLA and Founding President and CEO of the Buck Institute for Research on Aging in Novato, CA. His research has been published in the journal Aging (Sept. 27, 2014), and in EMBO Molecular Medicine (May 23, 2013) on next generation therapeutics for reversing Alzheimer’s disease. Here is a presentation he gave to the California State Assembly.

Listen to the Podcast:

The podcast of this program will be available the Monday after the broadcast date. The show can be streamed online from this site and podcasts can be downloaded for free for four weeks after the date of broadcast. After that time has passed, digital downloads are available for $2.99. CDs may be purchased at any time after broadcast for $9.99.

Buy the CD

Download the mp3

 

Rate this article
star-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-empty
4- 139 ratings
About the Author
Joe Graedon is a pharmacologist who has dedicated his career to making drug information understandable to consumers. His best-selling book, The People’s Pharmacy, was published in 1976 and led to a syndicated newspaper column, syndicated public radio show and web site. In 2006, Long Island University awarded him an honorary doctorate as “one of the country's leading drug experts for the consumer.” .
Get the latest health news right in your inbox

Join our daily email newsletter with breaking health news, prescription drug information, home remedies AND you'll get a copy of our brand new full-length health guide — for FREE!

Screenshots of The People's Pharmacy website on mobile devices of various sizes
Join over 150,000 Subscribers at The People's Pharmacy

We're empowering you to make wise decisions about your own health, by providing you with essential health information about both medical and alternative treatment options.